Report Adverse Event or Product Quality Complaint   US Site   Global Site             

Header Logo
  • Prescribing Information
  • Therapy areas
    • All Therapeutic Areas
    • Cardiovascular, Renal and Metabolism
    • Immunology
    • Infection
    • Oncology
    • Rare Disease (Alexion)
    • Respiratory
  • Disease Education
  • Resources
    • Congress Library
    • Clinical Trials
    • Continuing Education
    • Patient Support
    • Pipeline
  • Connect
    • Connect with an MSL
    • Connect with an MSL
    • Submit an MIR
    • Give Feedback

Search Medical Information

Login

Request a field medical follow-up

  • Home
  • Congress Library
  • American Academy of Allergy, Asthma & Immunology (AAAAI)

American Academy of Allergy, Asthma & Immunology (AAAAI): 82nd Annual Meeting - 2026

February 27 - March 2, 2026

  1. All
  2. AIRSUPRA (albuterol/budesonide)
  3. FASENRA (benralizumab)
  4. TEZSPIRE (tezepelumab)
  5. Respiratory Unbranded
  6. budesonide + glycopyrronium + formoterol

PDF

Efficacy of as needed albuterol–budesonide versus albuterol in participants with mild asthma not on maintenance therapy: BATURA post hoc analysis

HTML

Albuterol–budesonide treatment in acute airway obstruction provides enhanced lung function improvement for patients with well controlled and uncontrolled mild asthma

PDF

Use of as needed albuterol–budesonide is associated with a higher probability of symptom free nights than as needed albuterol in moderate to severe asthma

PDF

Benralizumab for severe eosinophilic asthma in pediatric patients: Rationale and design of the multicenter, randomized, double-blind, placebo-controlled phase 3 DOMINICA study

PDF

Long term efficacy of benralizumab in patients with severe eosinophilic asthma (SEA) and persistent airflow obstruction (PAO)

PDF

Improvements in hypereosinophilic syndrome (HES) symptoms and impacts with benralizumab: mixed-methods analysis of the NATRON in-trial interview sub-study

PDF

Efficacy of benralizumab by organ involvement in hypereosinophilic syndrome (HES): exploratory analyses from the NATRON study

PDF

Tezepelumab modulates expression of nasal polyp genes associated with polyp pathophysiology and epithelial health in chronic rhinosinusitis with nasal polyps: Results from the phase 3 WAYPOINT study

PDF

Tezepelumab increases probability of SNOT-22 low disease severity scores among people with CRSwNP (WAYPOINT)

PDF

Absence of hypereosinophilia in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) treated with tezepelumab: Results from the WAYPOINT study

PDF

Efficacy of tezepelumab in North American and European patients with CRSwNP, overall and by history of nasal polyp surgery: Results from the WAYPOINT study

PDF

Olfaction improvements following tezepelumab treatment: Efficacy by baseline symptoms, polyp burden and sinus opacification

PDF

Geographic variation in disease burden among patients with severe persistent asthma in the US, by age, sex, and race

PDF

The pediatric asthma impairment and risk questionnaire identifies disparities in morbidity between Hispanic/Latino and non-Hispanic White children better than other evaluations used in clinical practice

PDF

Biologic adherence and exacerbation risk among patients with severe asthma in the CHRONICLE study

PDF

Content validity and meaningful change thresholds of the Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form 7a in adults with hypereosinophilic syndrome (HES)

PDF

Treatment burden of oral corticosteroid monotherapy among patients with eosinophilic granulomatosis with polyangiitis: Real world evidence from a US claims study

PDF

Real-world rates of thrombotic events in patients with hypereosinophilic syndrome

PDF

Incidence and prevalence of hypereosinophilic syndrome (HES) in the US: a retrospective claims database study

PDF

Budesonide/Glycopyrrolate/Formoterol Fumarate Effects on Lung Function and Exacerbations by Baseline Exacerbation History in Inadequately-Controlled Asthma: Post Hoc Analyses of KALOS and LOGOS Studies

PDF

Efficacy of as needed albuterol–budesonide versus albuterol in participants with mild asthma not on maintenance therapy: BATURA post hoc analysis

HTML

Albuterol–budesonide treatment in acute airway obstruction provides enhanced lung function improvement for patients with well controlled and uncontrolled mild asthma

PDF

Use of as needed albuterol–budesonide is associated with a higher probability of symptom free nights than as needed albuterol in moderate to severe asthma

PDF

Benralizumab for severe eosinophilic asthma in pediatric patients: Rationale and design of the multicenter, randomized, double-blind, placebo-controlled phase 3 DOMINICA study

PDF

Long term efficacy of benralizumab in patients with severe eosinophilic asthma (SEA) and persistent airflow obstruction (PAO)

PDF

Improvements in hypereosinophilic syndrome (HES) symptoms and impacts with benralizumab: mixed-methods analysis of the NATRON in-trial interview sub-study

PDF

Efficacy of benralizumab by organ involvement in hypereosinophilic syndrome (HES): exploratory analyses from the NATRON study

PDF

Tezepelumab modulates expression of nasal polyp genes associated with polyp pathophysiology and epithelial health in chronic rhinosinusitis with nasal polyps: Results from the phase 3 WAYPOINT study

PDF

Tezepelumab increases probability of SNOT-22 low disease severity scores among people with CRSwNP (WAYPOINT)

PDF

Absence of hypereosinophilia in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) treated with tezepelumab: Results from the WAYPOINT study

PDF

Efficacy of tezepelumab in North American and European patients with CRSwNP, overall and by history of nasal polyp surgery: Results from the WAYPOINT study

PDF

Olfaction improvements following tezepelumab treatment: Efficacy by baseline symptoms, polyp burden and sinus opacification

PDF

Geographic variation in disease burden among patients with severe persistent asthma in the US, by age, sex, and race

PDF

The pediatric asthma impairment and risk questionnaire identifies disparities in morbidity between Hispanic/Latino and non-Hispanic White children better than other evaluations used in clinical practice

PDF

Biologic adherence and exacerbation risk among patients with severe asthma in the CHRONICLE study

PDF

Content validity and meaningful change thresholds of the Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form 7a in adults with hypereosinophilic syndrome (HES)

PDF

Treatment burden of oral corticosteroid monotherapy among patients with eosinophilic granulomatosis with polyangiitis: Real world evidence from a US claims study

PDF

Real-world rates of thrombotic events in patients with hypereosinophilic syndrome

PDF

Incidence and prevalence of hypereosinophilic syndrome (HES) in the US: a retrospective claims database study

PDF

Budesonide/Glycopyrrolate/Formoterol Fumarate Effects on Lung Function and Exacerbations by Baseline Exacerbation History in Inadequately-Controlled Asthma: Post Hoc Analyses of KALOS and LOGOS Studies

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Connessiallasalute.it

This site is intended for healthcare professionals practicing in the US.
©2026 AstraZeneca. All rights reserved.

US-107328
Last Updated 3/26

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities  

Survey Feedback

Your Privacy Choice

Consumer Health Data 
Privacy Notice

Privacy Notice | Legal Notice | Cookie Preferences

Welcome to AstraZeneca Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

 

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

 

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?
This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am not a healthcare professional practicing in the United States